169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. (25th April 2018) - Chinoy, Hector; Gossec, Laure; Kvien, Tore K; Conaghan, Philip G; Østergaard, Mikkel; Gladman, Dafna; Mease, Philip; Rasouliyan, Lawrence; Pricop, Luminita; Gaillez, Corine; Jugl, Steffen